Table of Contents Author Guidelines Submit a Manuscript
Cardiology Research and Practice
Volume 2016, Article ID 2868604, 8 pages
Clinical Study

RyR2 QQ2958 Genotype and Risk of Malignant Ventricular Arrhythmias

1Department of Biological and Environmental Sciences and Technologies, University of Salento, 73100 Lecce, Italy
2Department of Cardiology, “Card. G. Panico” Hospital, Tricase, 73039 Lecce, Italy

Received 20 October 2015; Accepted 5 January 2016

Academic Editor: Kai Hu

Copyright © 2016 Francesca Galati et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Ventricular arrhythmias are one of the most common causes of death in developed countries. The use of implantable cardiac defibrillators is the most effective treatment to prevent sudden cardiac death. To date, the ejection fraction is the only approved clinical variable used to determine suitability for defibrillator placement in subjects with heart failure. The purpose of this study was to assess whether genetic polymorphisms found in the ryanodine receptor type 2 (Q2958R) and histidine-rich calcium-binding protein (S96A) might serve as markers for arrhythmias. Genotyping was performed in 235 patients treated with defibrillator for primary and secondary prevention of arrhythmias. No significant association was found between the S96A polymorphism and arrhythmia onset, whereas the QQ2958 genotype in the ryanodine receptor gene was correlated with an increased risk of life-threatening arrhythmias. Concurrent stressor conditions, such as hypertension, seem to increase this effect. Our findings might help to better identify patients who could benefit from defibrillator implantation.